Our Pricing

Real Wegovy BMI Results: Clinical Evidence from UK

Searching for reliable wegovy bmi results uk data? Clinical trials demonstrate that Wegovy (semaglutide 2.4mg) can help patients achieve an average BMI reduction of 5-6 points over 68 weeks, with some participants losing up to 17.4% of their starting body weight [1]. At Cured Pharmacy, our UK-registered clinical team prescribes genuine Wegovy from £79.00, following a free online consultation that takes under three minutes.

What the STEP Clinical Trials Tell Us About Wegovy BMI Results UK

The STEP (Semaglutide Treatment Effect in People with Obesity) programme represents the largest body of evidence for Wegovy's effectiveness in the UK and globally [1]. Across five major trials involving over 4,500 participants, researchers measured BMI changes, waist circumference reduction, and cardiometabolic improvements in adults with obesity or overweight with weight-related comorbidities.

In STEP 1—the pivotal trial that informed MHRA licensing—participants using Wegovy 2.4mg weekly achieved an average weight loss of 14.9% compared to 2.4% with placebo over 68 weeks [1]. For a patient starting at BMI 38 (approximately 108kg at 170cm height), this translates to a BMI reduction of approximately 5.7 points, bringing them down to a BMI of 32.3. Importantly, 86.4% of Wegovy-treated participants achieved at least 5% weight loss, and 69.1% lost 10% or more [1].

STEP 5 extended the observation period to 104 weeks, demonstrating sustained BMI reduction with an average weight loss of 15.2% maintained beyond two years [2]. This long-term data addresses a critical question many UK patients ask: whether Wegovy results plateau or reverse after the first year. The evidence shows continued benefit when treatment is maintained alongside lifestyle modifications.

How Wegovy Works to Reduce BMI

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural gut hormone involved in appetite regulation and glucose metabolism [3]. Unlike older weight loss medications that work peripherally, semaglutide acts on receptors in the brain's appetite centres, reducing hunger signals and increasing feelings of fullness after smaller meals.

The medication also slows gastric emptying, meaning food stays in your stomach longer, which contributes to prolonged satiety between meals [3]. This dual mechanism—central appetite suppression and delayed gastric transit—explains why clinical trial participants reported finding it easier to adhere to reduced-calorie diets without the intense hunger that often derails weight loss efforts.

Wegovy is administered as a once-weekly subcutaneous injection, starting at 0.25mg and gradually escalating to the maintenance dose of 2.4mg over 16-20 weeks. This dose escalation schedule, developed through clinical trials, minimises gastrointestinal side effects whilst allowing your body to adapt to the medication's effects [1].

Who Qualifies for Wegovy in the UK

Under MHRA licensing and NICE guidance, Wegovy is indicated for adults with a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [4]. UK prescribers assess your medical history, current medications, and weight loss goals during the clinical consultation to determine suitability. All prescriptions at Cured Pharmacy are issued following assessment by a UK-registered prescriber, in full compliance with GPhC regulations.

Wegovy BMI Results UK: What to Expect in Your First 6 Months

Most patients begin noticing weight changes within the first 4-8 weeks of starting Wegovy, though initial results during the dose escalation phase are modest [1]. During weeks 1-4 at the 0.25mg starting dose, you may lose 1-2kg as your appetite begins to regulate. This is intentional—the gradual escalation allows your body to adapt whilst minimising nausea and other gastrointestinal effects.

By week 20, when you reach the full 2.4mg maintenance dose, clinical trial data shows patients had achieved approximately 10-12% of their total weight loss [1]. For someone starting at BMI 35, this represents a BMI reduction of roughly 3.5-4 points. The most significant weight loss typically occurs between weeks 20 and 60, as you maintain the therapeutic dose alongside dietary and activity modifications.

Individual results vary considerably based on adherence, baseline metabolic health, and lifestyle factors. In our experience at Cured Pharmacy, patients who combine Wegovy with structured nutritional support and regular physical activity tend to achieve results closer to the upper range reported in clinical trials. Your UK prescriber will monitor your progress and may adjust your treatment plan if you're not achieving at least 5% weight loss by week 16 on the maintenance dose, in line with NICE guidance [4].

Managing Side Effects During Treatment

The most commonly reported side effects in STEP trials were gastrointestinal: nausea (44%), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. These effects are typically mild to moderate, occur most frequently during dose escalation, and diminish over time as your body adapts. Eating smaller, more frequent meals and avoiding high-fat foods can help manage these symptoms. If side effects persist or become severe, your prescriber may slow the dose escalation or pause treatment temporarily.

Comparing Wegovy BMI Results to Other UK Weight Loss Treatments

When UK patients research weight loss medications, they often compare Wegovy to other licensed options. Orlistat, available over the counter for BMI ≥28, works by blocking fat absorption in the gut and produces an average weight loss of 3-5% over 12 months—significantly less than Wegovy's 15-17% [5]. Orlistat also requires strict dietary fat restriction to avoid unpleasant gastrointestinal effects.

Saxenda (liraglutide 3mg) is another GLP-1 receptor agonist, but requires daily injections rather than weekly dosing. Clinical trials of Saxenda showed average weight loss of 8% over 56 weeks—effective, but roughly half the magnitude seen with Wegovy [6]. The daily injection schedule can also affect long-term adherence for some patients.

Mounjaro (tirzepatide), a newer dual GIP/GLP-1 receptor agonist, has shown even greater weight loss in trials—up to 22.5% in the SURMOUNT programme [7]. However, Mounjaro is currently licensed in the UK primarily for type 2 diabetes, with weight management licensing expected. Your UK prescriber will help you understand which medication aligns best with your medical profile, preferences, and treatment goals.

Long-Term BMI Maintenance After Wegovy Treatment

A critical question for anyone considering Wegovy is what happens when treatment stops. The STEP 4 trial specifically examined this by randomising participants who had been on Wegovy for 20 weeks to either continue treatment or switch to placebo [2]. Those who discontinued Wegovy regained approximately two-thirds of their lost weight over the subsequent 48 weeks, whilst those who continued maintained their weight loss.

This data suggests that Wegovy is most effective as a long-term treatment rather than a short-term intervention. The MHRA has licensed it for chronic weight management, recognising that obesity is a chronic relapsing condition requiring ongoing treatment, much like hypertension or type 2 diabetes [4]. Many patients at Cured Pharmacy continue treatment for 12-24 months or longer, with regular prescriber reviews every three months to assess ongoing benefit and tolerability.

Behavioural changes established during treatment—such as portion control, mindful eating, and regular physical activity—become crucial for maintaining results if you eventually discontinue Wegovy. Working with a dietitian or weight management service alongside pharmacological treatment can help embed these sustainable habits.

When to Consider Stopping Treatment

NICE guidance recommends discontinuing Wegovy if you haven't achieved at least 5% weight loss after 6 months on the maintenance dose, as you're unlikely to achieve clinically meaningful benefit with continued treatment [4]. Your prescriber will also reassess treatment if you experience persistent side effects, develop contraindications, or reach your target weight and wish to attempt maintenance through lifestyle measures alone. Any decision to stop should be made collaboratively with your UK healthcare provider, with a plan for ongoing weight monitoring.

How to Start Wegovy Treatment at Cured Pharmacy

Starting your Wegovy treatment journey at Cured Pharmacy begins with a free online consultation that takes under three minutes to complete. You'll answer questions about your current weight, height, medical history, existing medications, and weight loss goals. This information is reviewed by our UK-registered prescribers, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), who will assess your suitability for treatment.

If Wegovy is deemed appropriate and safe for you, your prescription is issued electronically and dispensed from our GPhC-registered pharmacy (9012511). We supply only genuine UK-licensed Wegovy pens, delivered in discreet packaging directly to your address. Your first prescription will include the 0.25mg starting dose pens along with clear instructions for dose escalation and injection technique.

Wegovy is priced from £79.00 at Cured Pharmacy, with transparent pricing shown before you complete your consultation—no hidden fees or surprise charges. We offer the lowest prices guaranteed in the UK for genuine licensed medicines. Follow-up prescriptions can be ordered through your patient account, with ongoing prescriber reviews to monitor your progress and adjust treatment as needed. You can contact our clinical team on (+44) 116 4646009 if you have questions during your treatment.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
3. Nauck, M. A., et al. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875
5. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155
6. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
7. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence, lifestyle modifications, and baseline health status.